WallStSmart

Ambev SA ADR (ABEV)vsTenet Healthcare Corporation (THC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ambev SA ADR generates 314% more annual revenue ($88.24B vs $21.31B). ABEV leads profitability with a 17.6% profit margin vs 6.6%. ABEV appears more attractively valued with a PEG of 2.02. THC earns a higher WallStSmart Score of 66/100 (B-).

ABEV

Buy

55

out of 100

Grade: C

Growth: 2.7Profit: 8.5Value: 7.3Quality: 5.8
Piotroski: 5/9Altman Z: 2.39

THC

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.5Value: 7.3Quality: 6.3
Piotroski: 6/9Altman Z: 1.67
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABEVSignificantly Overvalued (-136.4%)

Margin of Safety

-136.4%

Fair Value

$1.29

Current Price

$2.85

$1.56 premium

UndervaluedFair: $1.29Overvalued
THCUndervalued (+68.8%)

Margin of Safety

+68.8%

Fair Value

$724.93

Current Price

$200.04

$524.89 discount

UndervaluedFair: $724.93Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABEV4 strengths · Avg: 8.5/10
Free Cash FlowQuality
$11.62B10/10

Generating 11.6B in free cash flow

P/E RatioValuation
14.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Operating MarginProfitability
28.2%8/10

Strong operational efficiency at 28.2%

THC3 strengths · Avg: 8.3/10
Return on EquityProfitability
27.0%9/10

Every $100 of equity generates 27 in profit

P/E RatioValuation
12.9x8/10

Attractively priced relative to earnings

EPS GrowthGrowth
27.6%8/10

Earnings expanding 27.6% YoY

Areas to Watch

ABEV3 concerns · Avg: 2.7/10
PEG RatioValuation
2.024/10

Expensive relative to growth rate

Revenue GrowthGrowth
-8.2%2/10

Revenue declined 8.2%

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

THC3 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.674/10

Distress zone — elevated risk

Profit MarginProfitability
6.6%3/10

6.6% margin — thin

PEG RatioValuation
4.692/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ABEV

The strongest argument for ABEV centers on Free Cash Flow, P/E Ratio, Price/Book. Profitability is solid with margins at 17.6% and operating margin at 28.2%.

Bull Case : THC

The strongest argument for THC centers on Return on Equity, P/E Ratio, EPS Growth.

Bear Case : ABEV

The primary concerns for ABEV are PEG Ratio, Revenue Growth, EPS Growth.

Bear Case : THC

The primary concerns for THC are Altman Z-Score, Profit Margin, PEG Ratio.

Key Dynamics to Monitor

ABEV profiles as a declining stock while THC is a value play — different risk/reward profiles.

THC carries more volatility with a beta of 1.41 — expect wider price swings.

THC is growing revenue faster at 8.9% — sustainability is the question.

ABEV generates stronger free cash flow (11.6B), providing more financial flexibility.

Bottom Line

THC scores higher overall (66/100 vs 55/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ambev SA ADR

CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA

Ambev SA produces, distributes and sells beer, draft beer, carbonated soft drinks (CSD), other non-alcoholic beverages, malt and food products in the Americas. The company is headquartered in So Paulo, Brazil.

Tenet Healthcare Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Tenet Healthcare Corporation is a diversified health services company. The company is headquartered in Dallas, Texas.

Want to dig deeper into these stocks?